Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.

Valeria CaponnettoAntonio RussoMarcello SilvestroAlessandro TessitoreRoberto De IccoGloria VaghiGrazia SancesCristina TassorelliCarlo BaraldiFlavia Lo CastroSimona GuerzoniMaria Pia PrudenzanoAdriana FallacaraMartino GentileRaffaele OrnelloAgnese OnofriAndrea BurgalassiAlberto ChiarugiFrancesco De CesarisAntonio GranatoAlfonsina CasalenaMarina De TommasoEdoardo MampresoPaola MerloGianluca CoppolaStefania BattistiniValentina RebecchiInnocenzo RaineroFederica Nicoletta SepeGiorgio Dalla VoltaSimona SaccoPierangelo GeppettiLuigi Francesco Iannonenull null

Published in: CNS drugs (2023)

This study provides evidence for the real-world effectiveness of fremanezumab in treating both high-frequency episodic migraine and chronic migraine, with meaningful and sustained improvements in multiple migraine-related variables. No new safety issue was identified.

Keyphrases

drug resistant
high frequency
multidrug resistant
transcranial magnetic stimulation
acinetobacter baumannii
cross sectional
pseudomonas aeruginosa
drug induced
double blind
smoking cessation